Lilly, Yabao collaborate on diabetes

Share this article:

Indiana's Eli Lilly has paired up with Beijing's Yabao Pharmaceutical to develop Lilly's experimental glucokinase activator LY2608204. The partners describe the pipeline treatment in a statement as a possible new way to address diabetes. The idea is that the activator would promote insulin secretion and lower the liver's glucose production, a combination the drug partners say “may exert powerful anti-hyperglycemic effects.”

The deal gives Yabao development and commercialization rights in China, while Lilly holds onto rights in all other geographies.

Data from the International Diabetes Foundation, which is comprised of diabetes associations in 170 countries and territories, indicates that China has the largest number of diabetics, with 98.4 million as of 2013. The IDF ranks the United States third, with 24.4 million, behind India, which counted 65.1 million last year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.